In patients undergoing chemotherapy for the treatment of malignant disease, the reactivation of hepatitis B virus in hepatitis B surface antigen-positive patients has been frequently reported. However, activation has also been reported in hepatitis B surface antigen-negative patients who test positive for hepatitis B core antibody and/or hepatitis B surface antibody, who were thought to have had transient infections and to have been cured. Reactivation has often been reported in patients receiving rituximab-containing regimens and has attracted a lot of attention in recent years. In Japan, 1 -3% of patients undergoing chemotherapy are hepatitis B surface antigen-positive, and 20 -25% of patients are hepatitis B surface antigen-negative with hepatitis B core antibody and/or hepatitis B surface antibody positivity; therefore, about one out of every four patients undergoing chemotherapy may be at risk for the reactivation of hepatitis B virus. In most of the guidelines for hepatitis B virus reactivation, the prophylactic administration of an antiviral drug in hepatitis B surface antigen-positive patients is recommended, and periodic monitoring of hepatitis B virus DNA and the deferred pre-emptive administration of an antiviral drug after conversion to hepatitis B virus DNA positivity are recommended in hepatitis B surface antigen-negative patients who are hepatitis B core antibody-positive and/or hepatitis B surface antibody-positive when chemotherapy has been scheduled. However, numerous issues regarding hepatitis B virus reactivation, including the frequency, the types of anticancer drugs, the cancers that facilitate hepatitis B virus reactivation and the optimal method of management, etc., have not been fully clarified. A variety of well-designed prospective studies are currently under way in both Japan and abroad, and strong evidence of hepatitis B virus reactivation following chemotherapy is anticipated in the future.
INTRODUCTION
Liver dysfunction is caused by a variety of anticancer drugs and their metabolites. Among these liver dysfunctions, a rapid increase in the growth of hepatitis viruses sometimes occurs, which can lead to fatal liver damage in patients who harbor hepatitis viruses and are receiving chemotherapy. The rapid growth of hepatitis viruses is classified as the reactivation of viral hepatitis. The reactivation of hepatitis C virus leading to severe hepatitis is certainly less common than that of hepatitis B virus (HBV), and the associations with chemotherapy have not been sufficiently elucidated (1) . However, the reactivation of HBV has often been reported in patients undergoing chemotherapy (1 -4) , especially those with malignant lymphoma who are receiving combination chemotherapy involving rituximab (5 -7) . Reports of the reactivation of HBV after treatment with other molecularly targeted drugs have also been recently increasing (8, 9) . The reactivation of HBV has frequently been found in hepatitis B surface antigen (HBsAg)-positive patients. In recent years, however, the reactivation of HBV has been reported even in HBsAg-negative patients who are positive for hepatitis B core antibody (HBcAb) or hepatitis B surface antibody (HBsAb) and who were thought to have had transient infections and to have been cured (1 -7) . Thus, caution regarding the reactivation of hepatitis viruses following chemotherapy is warranted.
CASE DESCRIPTION OF HBV REACTIVATION (FIG. 1)
The patient was a 76-year-old woman with malignant lymphoma. Before chemotherapy, she was HBsAg-negative, HBcAb-positive and HBsAb-positive and her liver function was normal (aspartate aminotransferase [AST], 31 U/L; alanine aminotransferase [ALT], 15 U/L; total-bilirubin [T-Bil], 1.2 mg/dl). She had undergone cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy combined with rituximab for 7 months without receiving antiviral therapy for HBV or HBV DNA monitoring. A complete remission of the malignant lymphoma was achieved, and the chemotherapy was terminated. At the time, her liver function was within the normal range (AST, 25 U/L; ALT, 11 U/L; T-Bil, 0.7 mg/dl). Seven months after the termination of the chemotherapy, severe liver dysfunction suddenly occurred (AST, 438 U/L; ALT, 326 U/L; T-Bil, 1.2 mg/dl). At the time of the severe liver dysfunction, the HBsAg status became positive, and the HBV DNA level increased to 9.7 log copies/ml. She was diagnosed as having HBV reactivation following the administration of CHOP therapy with rituximab. Even though an oral antiviral drug (entecavir) was hastily prescribed, the patient's liver function deteriorated further (AST, 4118 U/L; ALT, 1899 U/L; T-Bil, 17.4 mg/dl), and she developed hepatic failure and died. A complete remission of her malignant lymphoma had been achieved and a cure had been expected, but her death as a result of HBV reactivation was an extremely sorrowful outcome. In the present case, the patient's liver dysfunction might have likely been prevented if proper management for HBV reactivation had been performed.
HBV REACTIVATION
HBV can sometimes be transmitted from mother to child during the immunotolerant period of infancy and early childhood. When infection occurs during this period, the recipient of the virus often becomes an asymptomatic carrier; in some patients, however, chronic hepatitis or liver cirrhosis may develop. In this state, patients are usually HBsAg-positive and HBV DNA is detected in their serum. When the immune response is suppressed by chemotherapy, HBV is reactivated and liver dysfunction is induced, sometimes progressing to a fulminant and fatal stage (10) .
After reaching adulthood, HBV can sometimes be transmitted through unhygienic procedures, such as sharing psychostimulant substances, narcotic needles or tattooing, through blood transfusion or through sexual contact. In many patients who become infected after reaching adulthood, the infection is transient and the patient improves after having developed acute hepatitis. Under such circumstances, the HBsAg status usually becomes negative, the HBcAb or HBsAb status becomes positive and HBV DNA cannot be detected in the patient's serum. Previously, HBV was thought to have been completely eradicated from the body in such patients (10) . However, Rehermann et al. reported that HBV continued to be present in the liver or peripheral mononuclear cells even after the improvement in liver function following a transient infection (11) . Moreover, when HBV remains latent in the liver or peripheral mononuclear cells for a long time, it can begin to proliferate once again if the immune response is suppressed by chemotherapy, and HBV reactivation sometimes occurs as a result of immunocompetent cells attacking liver cells infected with HBV once the immune suppression recovers after the completion of chemotherapy (1 -7) .
Thus, the risk of HBV reactivation must clearly be considered not only in asymptomatic carriers and chronic hepatitis patients, but also in patients who have been transiently infected and in whom the virus was thought to have been eradicated. Such HBV reactivation has generally been defined as follows (3,4): The patient was a 76-year-old female and had undergone rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy therapy for malignant lymphoma. Seven months after the commencement of the chemotherapy, a complete remission of the malignant lymphoma was achieved, and the chemotherapy was terminated. Seven months after the termination of the chemotherapy, the reactivation of hepatitis B reactivation suddenly occurred, and she developed hepatic failure and died, despite a treatment of an oral antiviral drug (entecavir). Cx, chemotherapy.
2. HBsAg-negative, and HBcAb-and/or HBsAb-positive patients † HBsAg becomes positive † HBV DNA becomes positive in patients whose HBV DNA level is below the sensitivity of detection
In Japan, 1 -3% of the adult population is reportedly HBsAg-positive and 20 -25% are HBsAg-positive with HBcAb and/or HBsAb positivity (4,6,12 -16) (Table 1) . Thus, 25% of the population of Japan, or about one out of every four patients, are said to be at risk for HBV reactivation when undergoing chemotherapy. In addition, the risk of HBV reactivation is thought to depend on the degree of immunosuppression (the intensity of the chemotherapy, whether immunosuppressive agents are administered in combination, the type of malignant tumor and the immune response in each patient etc.) and the characteristics of the HBV infection (viral load, HBV serological state etc.).
Regarding the degree of immunosuppression, associations have been reported with steroid combination chemotherapy, rituximab combination chemotherapy, hematopoietic stem cell transplantation, organ transplantation and the presence of malignant lymphoma; regarding the characteristics of the HBV infection, differences have been reported according to the serological state of HBV-associated markers (HBsAg, HBeAg) and the viral load of HBV DNA before chemotherapy (1 -4,6).
HBSAG-POSITIVE PATIENTS
Numerous reports have described the reactivation of HBV in HBsAg-positive patients with almost every type of malignant tumor and who were treated with a wide variety of anticancer drugs; in these reports, the incidence of HBV reactivation in HBsAg-positive patients was 20 -50% (9,12,17 -30) (Table 2) . Moreover, a recent report indicated that when the molecularly targeted drug everolimus was used to treat HBsAg-positive patients with unresectable hepatocellular carcinoma, HBV reactivation occurred in 7 (59.1%) of the 22 patients (9). Thus, HBV reactivation in HBsAg-positive patients is observed relatively frequently in almost every type of malignant tumor and anticancer drugs, and caution is required irrespective of the type of cancer or the chemotherapy regimen. reported that when systemic chemotherapy was used to treat 80 HBsAg-negative patients with malignant lymphoma, HBV reactivation was observed in 5 (6.25%) of them; all 5 of these patients were HBcAb-and/or HBsAb-positive, and rituximab and steroid combination chemotherapy had been performed in all 5 patients (7). Thus, it became evident that reactivation as a result of the combined use of chemotherapy with a high immunosuppressive effect, such as rituximab, or combination therapy with a steroid can occur even in HBsAg-negative patients with HBcAb and/or HBsAb positivity who were generally believed to have recovered from HBV infection and to have been virus-free (6,7,31 -35) (Table 3) . However, almost all these reports concerned patients with malignant lymphoma who had been treated with rituximab, and reports of HBV reactivation in patients with solid tumors or other treatment regimens have been rare.
HBSAG-NEGATIVE PATIENTS

RISK FACTORS FOR HBV REACTIVATION
The following risk factors for HBV reactivation have been reported: male gender, younger age, HBeAg positivity, high HBV DNA load, low titer of HBsAb at pretreatment, breast cancer, malignant lymphoma, concomitant steroid treatment, treatment with an anthracycline anticancer drug and treatment with rituximab (6,7,12,13,22,24 -27,31 -34,36 -42) ( Table 4) .
OUTCOME OF PATIENTS WHO DEVELOPED HBV REACTIVATION
The prognosis of patients who develop liver dysfunction because of HBV reactivation has been reported to be poor. hepatitis, resulting in a liver-related mortality rate of 26% and a mortality rate of 100% among the fulminant patients. Meanwhile, 45 (9%) out of 529 patients with acute hepatitis B developed fulminant hepatitis, and the liver-associated mortality rate was 4 overall and 47% among the fulminant patients. Thus, the rate of conversion to fulminant hepatitis 
as a result of HBV reactivation and the liver-related mortality rate were significantly higher among patients with HBV reactivation than among patients with acute hepatitis (44) . Thus, the prognosis of patients in whom HBV reactivation causes liver damage is extremely poor, and suppressing reactivation before it causes liver dysfunction is important.
COUNTERMEASURES AGAINST HBV REACTIVATION
There are two approaches to preventing liver damage as a result of HBV reactivation: the prophylactic administration of an antiviral drug before chemotherapy, and the periodic monitoring of HBV DNA levels and the deferred pre-emptive administration of an antiviral drug when conversion to HBV DNA positivity is detected.
HBSAG-POSITIVE PATIENTS
Lau et al. randomly assigned 30 HBsAg-positive lymphoma patients who were scheduled to receive systemic chemotherapy into a prophylactic lamivudine group of 15 patients and a control group of 15 patients, and they reported that HBV reactivation occurred significantly less frequently in the lamivudine group (0%) than in the control group (eight patients, 53%) (45) . In addition, a controlled study was conducted to evaluate the frequency of HBV reactivation by randomly assigning 76 patients with HBV-associated unresectable hepatocellular carcinoma to a prophylactic lamivudine therapy group and a control group when transcatheter arterial chemoembolization using epirubicin (50 mg/m 2 ) and cisplatin (60 mg/m 2 ) was performed (23) . The results showed a reduction in the frequency of reactivation (lamivudine group versus control group: 2.8 versus 40.5%, P , 0.001) and the frequency of hepatitis as a result of reactivation (lamivudine group versus control group: 2.8 versus 29.7%, P ¼ 0.003). Moreover, some meta-analyses of prophylactic lamivudine administration have already been reported (46, 47) , and the frequency of HBV reactivation, the proportion of deaths, the chemotherapy delay and the proportion of patients in whom chemotherapy was discontinued because HBV reactivation was shown to be lower in the prophylactic lamivudine groups. Thus, the prophylactic administration of antiviral drugs, such as lamivudine, has been shown to be useful in HBsAg-positive patients.
HBSAG-NEGATIVE PATIENTS WITH HBCAB AND/OR HBSAB POSITIVITY
The prevention of HBV reactivation has not been fully investigated in HBsAg-negative patients with HBcAb and/or HBsAb positivity. Previous reports show that in most of the patients who developed hepatitis, the hepatitis developed after the completion of chemotherapy. Moreover, an increase in HBV DNA has been reported to occur an average of 18.5 weeks before the onset of liver damage or hepatitis (6) (Fig. 2) , and it may be possible to prevent liver damage arising from HBV reactivation even when the HBV DNA level is monitored once a month and deferred pre-emptive treatment with an antiviral drug is administered after the detection of the conversion to HBV DNA positivity. However, the usefulness of periodic HBV DNA monitoring has not been fully clarified, and confirmation using a welldesigned prospective study is warranted. On the other hand, the prophylactic administration of an antiviral drug before chemotherapy in HBsAg-negative patients with HBcAb and/or HBsAb positivity is not recommended for economic reasons (48). (26, 36) Male sex (13, 27) Use of anthracyclines (12, 36, 41) Cancer type: malignant lymphoma (12, 36) Use of rituximab (6, 7, (32) (33) (34) 42) Cancer type: breast cancer (36, 37) Cancer type: liver cancer (22, 24) High HBV DNA level (36) (37) (38) HBeAg seropositive (12, 22, 24) High intrahepatic covalently closed circular DNA (cccDNA) (39) Low titer of HBsAb (31, 40) Elevated serum ALT level (25) Figure 2 . Pattern of hepatitis B viral reactivation in a hepatitis B surface antigen (HBsAg)-negative patient with hepatitis B core antibody (HBcAb) and/or hepatitis B surface antibody (HBsAb) positivity (7) . Hepatitis due to HBV reactivation often developed after the completion of chemotherapy in an HBsAg-negative patient with HBcAb and/or HBsAb positivity. An increase in hepatitis B virus DNA has been reported to occur an average of 18.5 weeks before the onset of liver damage or hepatitis (7).
HBV reactivation following chemotherapy
HBV REACTIVATION GUIDELINES
The number of reports regarding HBV reactivation following chemotherapy has been gradually increasing, and countermeasures against HBV reactivation are urgently needed. (Fig. 3 ). All these guidelines are similar in principal (Table 2 ). When chemotherapy is going to be performed, the prophylactic administration of an antiviral drug in HBsAg-positive patients is recommended, and the periodic monitoring of the HBV DNA level and deferred pre-emptive administration of an antiviral drug after the detection of conversion to HBV DNA positivity is recommended for HBsAg-negative patients with HBcAb and/or HBsAb positivity. A summary of the guidelines that have been published by the Ministry of Health, Labour and Welfare in Japan (48) is presented below (Fig. 3) .
SCREENING EXAMINATIONS
A screening examination for HBsAg should be performed in every patient scheduled to receive chemotherapy, and patients with a high risk of HBV reactivation should be identified.
HBSAG-POSITIVE PATIENTS
HBeAg, hepatitis B e antibody (HBeAb) and HBV DNA levels should be measured, and the patient's HBV-related status should be confirmed prior to the start of chemotherapy. Since a high risk of HBV reactivation exists, an antiviral drug should, in principle, be prophylactically administered before the commencement of chemotherapy. However, because patients with chronic hepatitis or liver cirrhosis as well as HBV carriers are sometimes included among HBsAg-positive patients, a consultation with a hepatologist is also recommended.
HBSAG-NEGATIVE PATIENTS
If a patient tests positive for either HBcAb or HBsAb, a risk of reactivation exists and the HBV DNA level should be quantitatively assayed. If the HBV DNA test is positive, an antiviral drug should be prophylactically administered. If the test is negative (below the sensitivity of detection), the HBV DNA level should be monitored monthly and the administration of an antiviral drug should be started after the detection of a conversion to positivity. As the rate of conversion to fulminant hepatitis and the liver-related mortality rate are high when an antiviral drug is administered after liver damage has occurred and the transaminases and total bilirubin levels have increased, the deferred pre-emptive administration of an antiviral drug before the onset of liver damage is important. If the patient is negative for both HBcAb and HBsAb, no risk of HBV reactivation exists, and periodic follow-up of the HBV DNA level is thought to be unnecessary.
RECOMMENDED ANTIVIRAL DRUGS FOR PROPHYLACTIC ADMINISTRATION
The usefulness of lamivudine as a prophylactic antiviral drug to prevent HBV reactivation has been demonstrated in some of the above-mentioned randomized, controlled trials (23, 45) and meta-analyses (46, 47) . However, because of problems regarding the therapeutic efficacy against HBV and the high frequency of HBV that is resistant to lamivudine, entecavir should be recommended for use in Japan (48). Jpn J Clin Oncol 2013;43(1) 13
TIMING OF THE TERMINATION OF PROPHYLACTIC ANTIVIRAL DRUG ADMINISTRATION
No clear evidence exists regarding the termination of the prophylactic administration of antiviral drugs. Once administration has been continued for 12 months after the completion of chemotherapy and a decrease in the ALT level to within the normal range and conversion to persistent HBV-DNA negativity have been achieved, the termination of the administration of the antiviral drug can be considered. However, HBV reactivation has sometimes been reported after the termination of the administration of an antiviral drug, and close follow-up is necessary for the next 12 months after the termination of antiviral drug administration. The recently reported recommendation regarding the safe withdrawal of antiviral drugs for chronic HBV patients (53) may also be referred to upon the termination of antiviral drug administration.
PROBLEMS REGARDING HBV REACTIVATION
Guidelines for the prevention of immunosuppressive therapy or chemotherapy-induced reactivation of HBV infection have been announced (48) , but the following issues should be noted: (i) patients who are HBsAg-negative with HBcAb and/or HBsAb positivity are regarded as a high-risk group, but the frequency of HBV reactivation, the types of anticancer drugs and the cancers that facilitate HBV reactivation, the clinical features of HBV reactivation and the optimal method of management etc. have not been sufficiently elucidated.
(ii) Regular HBV DNA monitoring once a month and the deferred pre-emptive administration of an antiviral drug is recommended when performing chemotherapy in patients who are HBsAg-negative with HBcAb and/or HBsAb positivity, but the usefulness of such measures has not been clarified. Furthermore, the provisional clinical opinion of the American Society of Clinical Oncology (ASCO), which was 
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HBV reactivation following chemotherapy published in 2010 (54), does not strongly recommend routine screening and the prophylactic use of antiviral drugs because the evidence was regarded as being insufficient to determine the net benefit. Thus, these guidelines were drafted in the absence of sufficient evidence of the ability to avoid the risk of HBV reactivation. At present, numerous well-designed prospective studies to clarify the present status of HBV reactivation are being conducted in Japan and in other countries (Table 5 ). In the future, the establishment of strong evidence regarding HBV reactivation is anticipated.
CONCLUSIONS
Because HBV reactivation is often observed following chemotherapy, even with recently developed molecularly targeted agents such as rituximab, and in patients who are HBsAg-negative with HBcAb and/or HBsAb positivity who are generally believed to have recovered from an HBV infection and to be free of the virus, HBV reactivation has attracted considerable attention in recent years. However, many issues regarding HBV reactivation have yet to be clarified, including how often reactivation actually occurs, which regimens involve a high risk of reactivation and how frequently monitoring should be performed. A variety of research is currently under way in both Japan and abroad, and strong evidence regarding HBV reactivation is anticipated in the future.
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